Kwang Dong Pharmaceutical co., ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1963)
Status: No NME R&D (1963)

Organization Overview

First Clinical Trial
2011
NCT01458197
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Dongkwang Pharm. Co., Ltd. | Kwang Dong Pharmaceutical co., ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

vitamin d3 (2 trials)

Drugs in Phase 3 Trials (2)

bremelanotide (Vyleesi) (1 trial)

dkp21102 (1 trial)

Drugs in Phase 2 Trials (1)

tarafenacin (1 trial)

Drugs in Phase 1 Trials (1)

kd101 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Drug-Related Side Effects and Adverse Reactions (Phase 1)

Overweight (Phase 1)

Urinary Bladder, Overactive (Phase 2)

Vitamin D Deficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 5